Journal article
Polyethylene glycated leukemia inhibitory factor antagonist inhibits human blastocyst implantation and triggers apoptosis by down-regulating embryonic AKT
S Lalitkumar, NR Boggavarapu, J Menezes, E Dimitriadis, JG Zhang, NA Nicola, K Gemzell-Danielsson, LPG Lalitkumar
Fertility and Sterility | Published : 2013
Abstract
Objective To study the effect of polyethylene glycated leukemia inhibitory factor (LIF) antagonist (PEGLA) in the human blastocyst viability and implantation process. Design In vitro study. Setting University hospital and research laboratory. Patient(s) Endometrial biopsy samples from fertile donors (n = 20), and surplus, frozen, good-quality human embryos obtained from an in vitro fertilization (IVF) clinic that survived thawing (n = 51). Intervention(s) Timed human endometrial biopsy on the day of luteinizing hormone peak + 4 days (LH + 4). Main Outcome Measure(s) Human embryo attachment rate, embryo quality, and expression of AKT and caspase-3. Result(s) PEGLA significantly reduced the em..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Supported by CONRAD, the Consortium for Industrial Collaboration in Contraceptive Research Program of the Contraceptive Research and Development Program, Eastern Virginia Medical School (Subproject CIG-02-82), Swedish Research Council (Vetenskapsradet), Swedish Council for Working Life and Social Research (FAS), the National Health and Medical Research Council of Australia (Grant 461219 to N.A.N. and J.G.Z.), and a grant from Conrad. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS to the Walter and Eliza Hall Institute and Prince Henry's Institute.